ABEO Annual CFO
-$37.01 M
+$6.47 M+14.89%
31 December 2023
Summary:
As of January 23, 2025, ABEO annual cash flow from operations is -$37.01 million, with the most recent change of +$6.47 million (+14.89%) on December 31, 2023. During the last 3 years, it has fallen by -$1.99 million (-5.68%). ABEO annual CFO is now -5724.47% below its all-time high of $658.00 thousand, reached on December 31, 1995.ABEO Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ABEO Quarterly CFO
-$12.23 M
+$450.00 K+3.55%
30 September 2024
Summary:
As of January 23, 2025, ABEO quarterly cash flow from operations is -$12.23 million, with the most recent change of +$450.00 thousand (+3.55%) on September 30, 2024. Over the past year, it has dropped by -$3.00 million (-32.47%). ABEO quarterly CFO is now -647.63% below its all-time high of $2.23 million, reached on December 31, 2006.ABEO Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ABEO TTM CFO
-$48.69 M
-$6.49 M-15.37%
30 September 2024
Summary:
As of January 23, 2025, ABEO TTM cash flow from operations is -$48.69 million, with the most recent change of -$6.49 million (-15.37%) on September 30, 2024. Over the past year, it has dropped by -$11.68 million (-31.57%). ABEO TTM CFO is now -22032.88% below its all-time high of $222.00 thousand, reached on March 31, 2014.ABEO TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ABEO Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +14.9% | -32.5% | -31.6% |
| 3 y3 years | -5.7% | -18.4% | -31.5% |
| 5 y5 years | +5.4% | +33.0% | +22.5% |
ABEO Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +43.6% | -112.9% | +59.6% | -31.6% | +26.0% |
| 5 y | 5-year | -5.7% | +43.6% | -659.9% | +59.6% | -39.0% | +26.0% |
| alltime | all time | -5724.5% | +43.6% | -647.6% | +59.6% | <-9999.0% | +26.0% |
Abeona Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$12.23 M(-3.5%) | -$48.69 M(+15.4%) |
| June 2024 | - | -$12.68 M(-12.8%) | -$42.20 M(+6.0%) |
| Mar 2024 | - | -$14.54 M(+57.4%) | -$39.80 M(+7.5%) |
| Dec 2023 | -$37.01 M(-14.9%) | -$9.23 M(+60.7%) | -$37.01 M(-11.4%) |
| Sept 2023 | - | -$5.75 M(-44.1%) | -$41.77 M(-2.4%) |
| June 2023 | - | -$10.28 M(-12.4%) | -$42.81 M(+3.1%) |
| Mar 2023 | - | -$11.74 M(-16.1%) | -$41.54 M(-4.5%) |
| Dec 2022 | -$43.48 M(-33.8%) | -$13.99 M(+106.0%) | -$43.48 M(-27.2%) |
| Sept 2022 | - | -$6.79 M(-24.7%) | -$59.75 M(-5.6%) |
| June 2022 | - | -$9.01 M(-34.1%) | -$63.29 M(-3.8%) |
| Mar 2022 | - | -$13.69 M(-54.8%) | -$65.77 M(+0.2%) |
| Dec 2021 | -$65.67 M(+87.5%) | -$30.26 M(+192.8%) | -$65.67 M(+77.4%) |
| Sept 2021 | - | -$10.33 M(-10.1%) | -$37.02 M(-1.0%) |
| June 2021 | - | -$11.49 M(-15.4%) | -$37.39 M(+5.7%) |
| Mar 2021 | - | -$13.59 M(+743.8%) | -$35.37 M(+1.0%) |
| Dec 2020 | -$35.02 M(-44.3%) | -$1.61 M(-85.0%) | -$35.02 M(-26.5%) |
| Sept 2020 | - | -$10.70 M(+12.9%) | -$47.66 M(-13.7%) |
| June 2020 | - | -$9.47 M(-28.4%) | -$55.21 M(-9.5%) |
| Mar 2020 | - | -$13.23 M(-7.1%) | -$60.97 M(-2.9%) |
| Dec 2019 | -$62.82 M(+60.6%) | -$14.25 M(-22.0%) | -$62.82 M(-4.2%) |
| Sept 2019 | - | -$18.25 M(+19.8%) | -$65.54 M(+16.4%) |
| June 2019 | - | -$15.24 M(+1.1%) | -$56.33 M(+12.4%) |
| Mar 2019 | - | -$15.08 M(-11.1%) | -$50.11 M(+28.1%) |
| Dec 2018 | -$39.11 M(+72.6%) | -$16.97 M(+87.7%) | -$39.11 M(+43.8%) |
| Sept 2018 | - | -$9.04 M(+0.2%) | -$27.19 M(+9.1%) |
| June 2018 | - | -$9.02 M(+121.0%) | -$24.92 M(+19.3%) |
| Mar 2018 | - | -$4.08 M(-19.1%) | -$20.88 M(-7.8%) |
| Dec 2017 | -$22.66 M(+74.1%) | -$5.05 M(-25.5%) | -$22.66 M(+7.9%) |
| Sept 2017 | - | -$6.77 M(+35.9%) | -$21.00 M(+15.3%) |
| June 2017 | - | -$4.98 M(-14.9%) | -$18.22 M(+11.4%) |
| Mar 2017 | - | -$5.86 M(+72.6%) | -$16.36 M(+25.7%) |
| Dec 2016 | -$13.01 M(+24.9%) | -$3.39 M(-14.9%) | -$13.01 M(+4.1%) |
| Sept 2016 | - | -$3.99 M(+28.0%) | -$12.50 M(+13.4%) |
| June 2016 | - | -$3.12 M(+23.8%) | -$11.02 M(+12.7%) |
| Mar 2016 | - | -$2.52 M(-12.5%) | -$9.78 M(-6.2%) |
| Dec 2015 | -$10.42 M(+547.0%) | -$2.88 M(+14.5%) | -$10.42 M(+20.5%) |
| Sept 2015 | - | -$2.51 M(+34.3%) | -$8.65 M(+37.8%) |
| June 2015 | - | -$1.87 M(-40.8%) | -$6.28 M(+35.0%) |
| Mar 2015 | - | -$3.16 M(+187.0%) | -$4.65 M(+188.6%) |
| Dec 2014 | -$1.61 M(<-9900.0%) | -$1.10 M(+687.1%) | -$1.61 M(+63.9%) |
| Sept 2014 | - | -$140.00 K(-42.6%) | -$983.00 K(-44.1%) |
| June 2014 | - | -$244.00 K(+95.2%) | -$1.76 M(-892.3%) |
| Mar 2014 | - | -$125.00 K(-73.6%) | $222.00 K(>+9900.0%) |
| Dec 2013 | $1000.00(-100.0%) | -$474.00 K(-48.3%) | $1000.00(-100.1%) |
| Sept 2013 | - | -$916.00 K(-152.7%) | -$1.14 M(+61.4%) |
| June 2013 | - | $1.74 M(-602.0%) | -$707.00 K(-78.0%) |
| Mar 2013 | - | -$346.00 K(-78.6%) | -$3.22 M(-18.6%) |
| Dec 2012 | -$3.96 M(-48.0%) | -$1.62 M(+235.3%) | -$3.96 M(-8.1%) |
| Sept 2012 | - | -$482.00 K(-37.8%) | -$4.30 M(-36.9%) |
| June 2012 | - | -$775.00 K(-28.4%) | -$6.82 M(-13.2%) |
| Mar 2012 | - | -$1.08 M(-44.9%) | -$7.85 M(+3.2%) |
| Dec 2011 | -$7.61 M | -$1.96 M(-34.5%) | -$7.61 M(+3.4%) |
| Sept 2011 | - | -$3.00 M(+65.5%) | -$7.36 M(+29.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2011 | - | -$1.81 M(+116.4%) | -$5.68 M(+3.1%) |
| Mar 2011 | - | -$837.00 K(-51.2%) | -$5.51 M(-19.7%) |
| Dec 2010 | -$6.86 M(+205.2%) | -$1.72 M(+30.5%) | -$6.86 M(+10.1%) |
| Sept 2010 | - | -$1.31 M(-19.7%) | -$6.23 M(+34.9%) |
| June 2010 | - | -$1.64 M(-25.2%) | -$4.62 M(+16.4%) |
| Mar 2010 | - | -$2.19 M(+101.7%) | -$3.97 M(+76.5%) |
| Dec 2009 | -$2.25 M(-75.9%) | -$1.09 M(-465.7%) | -$2.25 M(-23.1%) |
| Sept 2009 | - | $297.00 K(-130.1%) | -$2.92 M(-60.7%) |
| June 2009 | - | -$987.00 K(+109.1%) | -$7.45 M(+6.8%) |
| Mar 2009 | - | -$472.00 K(-73.2%) | -$6.97 M(-25.2%) |
| Dec 2008 | -$9.32 M(+92.5%) | -$1.76 M(-58.3%) | -$9.32 M(+1.8%) |
| Sept 2008 | - | -$4.23 M(+728.8%) | -$9.16 M(+61.1%) |
| June 2008 | - | -$510.00 K(-81.9%) | -$5.69 M(-10.8%) |
| Mar 2008 | - | -$2.83 M(+76.6%) | -$6.38 M(+31.7%) |
| Dec 2007 | -$4.84 M(+147.3%) | -$1.60 M(+112.5%) | -$4.84 M(+380.0%) |
| Sept 2007 | - | -$753.00 K(-37.2%) | -$1.01 M(-10.7%) |
| June 2007 | - | -$1.20 M(-7.1%) | -$1.13 M(-40.6%) |
| Mar 2007 | - | -$1.29 M(-157.8%) | -$1.90 M(-2.9%) |
| Dec 2006 | -$1.96 M(-73.2%) | $2.23 M(-355.6%) | -$1.96 M(-71.5%) |
| Sept 2006 | - | -$874.00 K(-55.7%) | -$6.87 M(-5.7%) |
| June 2006 | - | -$1.97 M(+46.3%) | -$7.29 M(-0.8%) |
| Mar 2006 | - | -$1.35 M(-49.8%) | -$7.35 M(+0.6%) |
| Dec 2005 | -$7.30 M(-13.2%) | -$2.68 M(+108.0%) | -$7.30 M(+7.5%) |
| Sept 2005 | - | -$1.29 M(-36.5%) | -$6.79 M(-9.4%) |
| June 2005 | - | -$2.03 M(+56.0%) | -$7.50 M(-2.0%) |
| Mar 2005 | - | -$1.30 M(-40.1%) | -$7.65 M(-9.1%) |
| Dec 2004 | -$8.41 M(+36.7%) | -$2.17 M(+8.9%) | -$8.41 M(+3.4%) |
| Sept 2004 | - | -$1.99 M(-8.6%) | -$8.13 M(-8.9%) |
| June 2004 | - | -$2.18 M(+5.6%) | -$8.93 M(+40.1%) |
| Mar 2004 | - | -$2.06 M(+9.2%) | -$6.37 M(+3.5%) |
| Dec 2003 | -$6.15 M(-28.4%) | -$1.89 M(-32.2%) | -$6.15 M(+0.2%) |
| Sept 2003 | - | -$2.79 M(-843.7%) | -$6.14 M(-1.2%) |
| June 2003 | - | $375.00 K(-120.3%) | -$6.21 M(-26.5%) |
| Mar 2003 | - | -$1.85 M(-1.6%) | -$8.46 M(-1.6%) |
| Dec 2002 | -$8.60 M(+63.0%) | -$1.88 M(-34.3%) | -$8.60 M(+9.0%) |
| Sept 2002 | - | -$2.86 M(+53.1%) | -$7.89 M(+10.7%) |
| June 2002 | - | -$1.87 M(-5.9%) | -$7.12 M(+10.2%) |
| Mar 2002 | - | -$1.99 M(+69.5%) | -$6.46 M(+22.6%) |
| Dec 2001 | -$5.27 M(+21.7%) | -$1.17 M(-44.1%) | -$5.27 M(+1.4%) |
| Sept 2001 | - | -$2.10 M(+73.4%) | -$5.20 M(+17.1%) |
| June 2001 | - | -$1.21 M(+52.1%) | -$4.44 M(+0.0%) |
| Mar 2001 | - | -$795.00 K(-27.7%) | -$4.44 M(+2.5%) |
| Dec 2000 | -$4.33 M(+33.5%) | -$1.10 M(-17.8%) | -$4.33 M(-3.2%) |
| Sept 2000 | - | -$1.34 M(+10.8%) | -$4.48 M(+13.7%) |
| June 2000 | - | -$1.21 M(+76.4%) | -$3.94 M(+18.3%) |
| Mar 2000 | - | -$685.00 K(-45.0%) | -$3.33 M(+2.6%) |
| Dec 1999 | -$3.25 M(+1.4%) | -$1.25 M(+55.6%) | -$3.25 M(+62.3%) |
| Sept 1999 | - | -$800.00 K(+33.3%) | -$2.00 M(+66.7%) |
| June 1999 | - | -$600.00 K(0.0%) | -$1.20 M(+100.0%) |
| Mar 1999 | - | -$600.00 K | -$600.00 K |
| Dec 1998 | -$3.20 M(-11.8%) | - | - |
| Dec 1997 | -$3.63 M(+36.0%) | - | - |
| Dec 1996 | -$2.67 M(-505.5%) | - | - |
| Dec 1995 | $658.00 K | - | - |
FAQ
- What is Abeona Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Abeona Therapeutics?
- What is Abeona Therapeutics annual CFO year-on-year change?
- What is Abeona Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Abeona Therapeutics?
- What is Abeona Therapeutics quarterly CFO year-on-year change?
- What is Abeona Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Abeona Therapeutics?
- What is Abeona Therapeutics TTM CFO year-on-year change?
What is Abeona Therapeutics annual cash flow from operations?
The current annual CFO of ABEO is -$37.01 M
What is the all time high annual CFO for Abeona Therapeutics?
Abeona Therapeutics all-time high annual cash flow from operations is $658.00 K
What is Abeona Therapeutics annual CFO year-on-year change?
Over the past year, ABEO annual cash flow from operations has changed by +$6.47 M (+14.89%)
What is Abeona Therapeutics quarterly cash flow from operations?
The current quarterly CFO of ABEO is -$12.23 M
What is the all time high quarterly CFO for Abeona Therapeutics?
Abeona Therapeutics all-time high quarterly cash flow from operations is $2.23 M
What is Abeona Therapeutics quarterly CFO year-on-year change?
Over the past year, ABEO quarterly cash flow from operations has changed by -$3.00 M (-32.47%)
What is Abeona Therapeutics TTM cash flow from operations?
The current TTM CFO of ABEO is -$48.69 M
What is the all time high TTM CFO for Abeona Therapeutics?
Abeona Therapeutics all-time high TTM cash flow from operations is $222.00 K
What is Abeona Therapeutics TTM CFO year-on-year change?
Over the past year, ABEO TTM cash flow from operations has changed by -$11.68 M (-31.57%)